Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.53 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036181 | 0.85 | KMT2A (0.50) | PSMD14COPS5CCR1CCR8 | |
| SCHEMBL14871760 | 0.81 | HTR1A (0.53) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL7247375 | 0.80 | NSD2 (0.54) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL28304013 | 0.80 | SLC40A1 (0.49) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL1714045 | 0.80 | KDM4E (0.54) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL6589147 | 0.80 | NR4A2 (0.56) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL12042114 | 0.80 | SLC40A1 (0.49) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL185654 | 0.80 | CCR1 (0.50) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL8032037 | 0.79 | CCR1 (0.69) | HTR1AADRA1DADRA1AADRA1BSLC40A1 | |
| SCHEMBL1715009 | 0.79 | SLC40A1 (0.48) | HTR1AADRA1DADRA1AADRA1BSLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| WO-2006007700-A1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
| US-4900751-A | 2-Pyridinyl-phenyl-sulphinyl-and-phenyl-thio-benzimidazoles having antiflammatory or gastic acid secretion inhibition activity | FISONS PLC (GB) | 1990-02-13 | — | — | US | disclosed |
| US-4851419-A | Certain 2-pyridinyl-phenylsulfinyl-benzoxazoles, the corresponding benzothiazoles or benzimidazoles having anti-inflammatory or gastric acid secretion inhibition activity | FISONS PLC (GB) | 1989-07-25 | — | — | US | disclosed |
| EP-0283504-A1 | COMPOUNDS | FISONS plc (GB) | 1988-09-28 | — | — | EP | disclosed |
| WO-1988002367-A1 | COMPOUNDS | FISONS PLC (GB) | 1988-04-07 | — | — | WO | disclosed |
| EP-0262845-A1 | Heterocyclic substituted azole derivatives | FISONS plc (GB) | 1988-04-06 | — | — | EP | disclosed |
| EP-0220053-A2 | Benzimidazoles, benzoxazoles, benzothiazoles and their production, formulation and use as gastric acid secretion inhibitors | FISONS plc (GB) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | HTR1A 3633/4885ADRA1D 3965/4885ADRA1A 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.